There's No Stock in the BlancOne Whitening Deal — Read It as a Lesson in How the Category Fails

A distributor in Edmonton just became the exclusive U.S. seller of an Italian teeth-whitening product. The press release calls it a "breakthrough approach" that will "transform how dental practices deliver whitening." Before reading further, check the one thing a retail investor actually needs to know: there is no stock to buy here. Andau Medical is a private, Alberta-based dental distributor, and IDS Spa, the Italian family firm that makes BlancOne, is private too. This announcement is not an investment. It is a window onto a category that keeps promising something it has not yet delivered.

Strip away the word "breakthrough" and you get a specific product decision. BlancOne's flagship Click+ treatment takes about ten minutes, needs no gum barrier, and claims little to no sensitivity because it uses a low concentration of peroxide activated by light rather than a heavy peroxide load. The detail that matters is not the chemistry. It is that the treatment is designed to slot into an existing hygiene appointment — the ten spare minutes a hygienist already has — instead of requiring a dedicated whitening visit. The product is built around a single bottleneck: how to sell whitening inside time that is already booked.

That is a real idea, and it explains the economics. Whitening is cash, out-of-pocket, and discretionary — insurers rarely touch it — so the way a dental practice draws it in matters as much as the demand itself. The global professional whitening market is roughly $2.7 billion and growing maybe 5 to 6 percent a year, spread across roughly 178,000 U.S. dental businesses where Philips' Zoom is the entrenched in-office name. The distributor's money comes from the pattern behind the lamp: sell the activation hardware once, then reorder the gel syringes that get used up when a hygienist actually offers the treatment. The recurring part is what would make this worth having.

Now look at how the deal is structured, because it tells you who thinks they are on the winning side. IDS Spa, the manufacturer, did not build a U.S. sales force. It handed Andau an exclusive territory. A few months earlier it did the same thing for a different distributor in Australia and New Zealand. Giving away an entire market in exchange for a distributor's relationships and education network is a bet that getting into the chair matters more than controlling the margin. It is the right bet if a door-to-door salesperson, a demo, and a training session are what it takes to change a hygienist's behavior. But exclusivity is also cheap to give away, which is a clue about how fragmented this business is: the manufacturer is franchising out the country one middleman at a time rather than trying to win it.

The same test applies regardless of where the product lands. Demand in this category is real — patients ask for whiter teeth, enough that this is a multi-billion-dollar market — yet the companies built on that demand keep failing. SmileDirectClub rode the at-home version to a valuation near nine billion dollars and never turned a profit before going bankrupt. Retail and in-office players have not done much better at building durable, compoundable businesses. The difference between a real and a fake version of this story shows up in one behavior: whether practices reorder the consumables on their own, because their patients ask for the treatment again, or whether the reps have to keep pushing demos to keep the pipeline full. Pull is a business. Push is a novelty.

I haven't thought deeply about dental distribution, but the frame transfers. When you read an "exclusive distributorship" headline, three questions decide whether it is even worth your time. Is there a public company you can own, or are you just watching a private middleman collect a fee? Who captures the value that repeats — the hardware sale, or the refill that happens because people actually use it? And is the demand pull from the end user, or push from the sales force? The manufacturers give away exclusivity precisely because they doubt they can generate pull at scale. Believing the opposite is what the next ten years of whitening headlines will keep asking you to do.